Wuhan Hiteck Biological Pharma (300683.SZ) has approved its subsidiary ZM-02 eye injection to conduct clinical trials.

Wuhan Hiteck Biological Pharma (300683.SZ) announced that its invested company, Zhongmou Medical Technology (Wuhan) Co., Ltd. (referred to as Zhongmou Medical), has received the approval notice for drug clinical trials issued by the National Medical Products Administration. The clinical trial application for its independently developed ZM-02 ophthalmic injection has been approved, allowing for clinical trials to treat advanced retinitis pigmentosa. It is reported that ZM-02 is a next-generation optogenetic gene therapy independently developed by Zhongmou Medical for treating advanced retinal degenerative diseases. This therapy delivers a novel light-sensitive protein gene to retinal cells through a single vitrectomy injection, enabling patients to perceive light signals even in the absence of functional photoreceptors. Unlike traditional therapies that target specific gene mutations, ZM-02 employs a non-gene mutation site-dependent strategy, making it broadly applicable to both hereditary and acquired retinal degenerative diseases, such as age-related macular degeneration.